X0508 4/A 2025-05-20 2025-05-22 0001799011 Lucid Diagnostics Inc. LUCD 0001817012 Matheis Dennis 360 MADISON AVENUE, 25TH FLOOR NEW YORK NY 10017 1 0 0 0 0 Common Stock 2025-05-20 4 P 0 187098 1.2950 A 402541 D Common Stock 2025-05-21 4 P 0 129684 1.3226 A 532225 D Common Stock 2025-05-22 4 P 0 33218 1.3184 A 565443 D The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive. Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner. The reporting person is filing this amendment to the Form 4 initially filed on May 22, 2025 solely to correct the number of shares beneficially owned by the reporting person following the reported transactions. The initial filing omitted from this amount 215,443 shares (which includes the 52,718 shares referenced in footnote 4) held by the reporting person prior to the reported transactions. /s/ Michael A. Gordon, by power of attorney 2025-05-22